You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金斯瑞生物科技(01548.HK)公佈中期業績 收益增加32.7%至約3.05億美元 研發開支達約1.77億美元
格隆匯 08-31 21:35

格隆匯8月31日丨金斯瑞生物科技(01548.HK)發佈公吿,截至2022年6月30日止六個月,公司收益約為3.05億美元,同比增加32.7%,其中非細胞療法業務的外部收益約為2.48億美元,同比增加26.6%,細胞療法業務的外部收益約為5700萬美元,同比增加68.1%。

期間集團的毛利約為1.755億美元,同比增加26.6%,其中非細胞療法業務的毛利(抵銷前)約為1.26億美元,同比增加16.4%,細胞療法業務的毛利(抵銷前)約為5210萬美元,同比增加53.7%。

於報吿期內,集團大量投入研發活動及人才招聘,兩者均是業務長期可持續增長的主要推動因素。期間集團的研發開支約為1.77億美元,而2021年同期約為1.75億美元。

集團的業務營運覆蓋全球逾100個國家,法人實體遍及美國、中國內地、香港、日本、新加坡、荷蘭、愛爾蘭、英國、韓國及比利時。截至2022年6月30日,公司的專業團隊僱員數目已增加至約5,573人。

集團的長期戰略是將研發及資本投資集中於GCT領域,不僅開發CARVYKTITM等創新細胞治療產品,同時亦開發GCT相關研究及生產過程中的支持技術。公司相信,公司的產品及服務在服務該市場快速增長的需求方面具有很強的競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account